News Chart MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-18 EDT			5-day change	1st Jan Change
39.49 ^USD	-1.69%		-8.80%	-34.61%

06-10	MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from Both FDA and EMA on Path for the Phase 3 Program for the Nanobody Sonelokimab in Psoriatic Arthritis	CI
05-07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT

35593a7f27230901089604a6de.mWbQRaZfMEZUgt_l6473V2fHGaQ16moMRDrJi-5QYtw.0Te4Ae8ccSxh74fRuveoGlOzf_tyjl41Cg6QxYE-JL_cNeQRi29xEh_vig~c2290eddc6d2fd912c9ac98af022954d